GoodRx Holdings, Inc. - Class A Common Stock (GDRX)
3.7500
-0.1400 (-3.60%)
NASDAQ · Last Trade: Oct 22nd, 2:27 PM EDT
Detailed Quote
Previous Close
3.890
Open
3.900
Bid
3.740
Ask
3.750
Day's Range
3.730 - 3.900
52 Week Range
3.305 - 6.927
Volume
1,952,122
Market Cap
1.55B
PE Ratio (TTM)
37.50
EPS (TTM)
0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,729,864
Chart
About GoodRx Holdings, Inc. - Class A Common Stock (GDRX)
GoodRx Holdings Inc is a healthcare technology company that provides consumers with affordable access to prescription medications. Through its platform, GoodRx offers price comparisons for prescription drugs at various pharmacies, enabling users to find the lowest available prices. In addition to its pricing tools, the company offers discount coupons, telehealth services, and health information resources, ultimately striving to improve transparency and cost-effectiveness in the prescription drug market. Its services aim to empower consumers in making informed choices about their healthcare needs. Read More
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative "a good start," while still acknowledging its limitations.
Over the past six months, GoodRx’s stock price fell to $3.94. Shareholders have lost 9.8% of their capital, which is disappointing considering the S&P 500 has climbed by 30.6%. This was partly due to its softer quarterly results and might have investors contemplating their next move.
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription for hair loss treatment. Built for simplicity and transparency, GoodRx for Hair Loss helps men access affordable treatments that are clinically proven to slow hair loss and support regrowth.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology industry, including GoodRx (NASDAQ:GDRX) and its peers.
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 13.9% gain for healthcare stocks has fallen short of the S&P 500’s 32.7% rise.
Shares of healthcare tech company GoodRx (NASDAQ:GDRX)
jumped 1.4% in the afternoon session after the stock's positive momentum continued following a potential partnership with TrumpRx and an expanded relationship with Kroger.
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of its brand medication savings solution, RxSmartSaver powered by GoodRx, at Kroger pharmacies nationwide. RxSmartSaver brings medication affordability directly to the pharmacy counter, improving the patient experience while delivering stronger economics for the retail partner.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Shares of healthcare tech company GoodRx (NASDAQ:GDRX)
fell 4.9% in the afternoon session after a report on the U.S. job market raised concerns about a potential recession.
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., is riding into new creative territory with the launch of The Savings Wrangler, a groundbreaking brand campaign that aims to bring the company’s mission to life in an unforgettable way. Designed to deepen cultural relevance and brand resonance, the campaign introduces a lasso-wielding heroine – the Savings Wrangler – a lovable and fiercely dedicated cowgirl who’s on a mission to help Americans tame the Wild West of prescription pricing.
Shares of healthcare tech company GoodRx (NASDAQ:GDRX)
jumped 3.1% in the morning session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo Nordisk.
Shares of healthcare tech company GoodRx (NASDAQ:GDRX)
jumped 3.7% in the afternoon session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo Nordisk.
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.
A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this trend is that much of the recent market gains were concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed.
